Repertoire Immune Medicines
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Repertoire Immune Medicines
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Private Company Edition: VC mega-rounds boosted the Q1 2021 total. Also, new funds from Versant, The Column Group and Rapha Capital keep cash flowing into biopharma; up to $525m is invested in Exscientia; and Arch Oncology and Boundless Bio raised $105m each, while Forge brought in $120m.
The center is partnering with Obsidian to make autologous TILs work better after being infused back into patients by using IL-15, which may be less toxic than the high-dose IL-2 currently used.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Cogen Immune Medicines
- Cogen Therapeutics
- Torque Therapeutics